FAS and cholangiocarcinoma: The treatment of gemcitabine in CCA cell lines caused the increase in HLA class I expression and the death receptor, CD95 (Fas receptor) which could help to enhance the antigen presentation of the cancer cells and sensitize the cancer cells to activated T cells, respectively [14].